九洲藥業(603456.SH):子公司獲得高新技術企業認定
格隆匯12月13日丨九洲藥業(603456.SH)公佈,根據全國高新技術企業認定管理工作領導小組辦公室近日發佈的《對江蘇省認定機構2024年認定報備的第二批高新技術企業進行備案的公吿》,浙江九洲藥業股份有限公司全資子公司瑞博(蘇州)製藥有限公司已通過高新技術企業認定,證書編號為GR202432005007,發證時間為2024年11月19日,有效期為三年。瑞博蘇州本次高新技術企業認定系首次認定,根據國家相關規定,瑞博蘇州自本次獲得高新技術企業認定後三年內(2024年-2026年)將享受國家關於高新技術企業的相關税收優惠政策,即按15%的税率繳納企業所得税。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.